|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Articles in PresS, published online ahead of print May 6, 2002
Am J Physiol Regu Physiol, 10.1152/ajpregu.00602.2001
Submitted on October 3, 2001
Accepted on April 16, 2002
in normal and hypercholesterolemic pigs
1 Department of Internal Medicine, Division of Hypertension, Mayo Clinic, Rochester, MN, USA
2 Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
3 Department of Physiology and Biophysics, Mayo Clinic, Rochester, MN, USA
* To whom correspondence should be addressed. E-mail: Lerman.Lilach{at}Mayo.Edu.
Hypercholesterolemia (HC) is characterized by increased circulating 8-epi-Prostaglandin-F2
(Isoprostane), vasoconstrictor, marker, and mediator of increased oxidative stress, whose vascular effects might be augmented in HC. Anesthetized pigs were studied in vivo with electron-beam computed-tomography after a 12-week normal (n=8) or HC (n=8) diet. Mean arterial pressure (MAP), single-kidney perfusion and glomerular filtration rate (GFR) were quantified before and during unilateral intra-renal infusions of U46619 (10 ng/kg/min) or Isoprostane (1µg/kg/min). Basal renal perfusion and function were similar, and Isoprostane infusion elevated its systemic levels similarly in normal and HC (333±89 vs. 366±48 pg/mL, respectively, p<0.01 vs. baseline). Both drugs markedly and comparably decreased cortical perfusion and GFR in both groups, while medullary perfusion decreased significantly only in HC. Moreover, MAP increased significantly only in HC (+9±3 and +11±3mmHg, respectively, p
0.05). Hence, in HC renal functional responses to high-dose Isoprostane are largely similar to normal, but the systemic circulation exhibits augmented sensitivity to pathophysiological levels of Isoprostane and U46619, which may potentially play a role in development of hypertension and vascular injury associated with increased oxidative-stress.
This article has been cited by other articles:
![]() |
S. Lavi, E. H. Yang, A. Prasad, V. Mathew, G. W. Barsness, C. S. Rihal, L. O. Lerman, and A. Lerman The Interaction Between Coronary Endothelial Dysfunction, Local Oxidative Stress, and Endogenous Nitric Oxide in Humans Hypertension, January 1, 2008; 51(1): 127 - 133. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Spirou, E. Rizos, E. N. Liberopoulos, N. Kolaitis, A. Achimastos, A. D. Tselepis, and M. Elisaf Effect of Barnidipine on Blood Pressure and Serum Metabolic Parameters in Patients With Essential Hypertension: A Pilot Study Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2006; 11(4): 256 - 261. [Abstract] [PDF] |
||||
![]() |
S. Ogawa, T. Mori, K. Nako, T. Kato, K. Takeuchi, and S. Ito Angiotensin II Type 1 Receptor Blockers Reduce Urinary Oxidative Stress Markers in Hypertensive Diabetic Nephropathy Hypertension, April 1, 2006; 47(4): 699 - 705. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Daghini, A. R. Chade, J. D. Krier, D. Versari, A. Lerman, and L. O. Lerman Acute inhibition of the endogenous xanthine oxidase improves renal hemodynamics in hypercholesterolemic pigs Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R609 - R615. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Chade, J. D. Krier, M. Rodriguez-Porcel, J. F. Breen, M. A. McKusick, A. Lerman, and L. O. Lerman Comparison of acute and chronic antioxidant interventions in experimental renovascular disease Am J Physiol Renal Physiol, June 1, 2004; 286(6): F1079 - F1086. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Scholz Prostaglandins Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R512 - R514. [Full Text] [PDF] |
||||
![]() |
J. F. Reckelhoff and J. C. Romero Role of oxidative stress in angiotensin-induced hypertension Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R893 - R912. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |